Novo Nordisk A/S
NONOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.79 | -2.08 | 5.76 | 7.12 |
| FCF Yield | 2.08% | 1.25% | 0.47% | -0.15% |
| EV / EBITDA | 48.20 | 46.71 | 47.60 | 70.82 |
| Quality | ||||
| ROIC | 6.40% | 9.15% | 11.04% | 11.16% |
| Gross Margin | 76.12% | 83.29% | 83.49% | 84.80% |
| Cash Conversion Ratio | 2.30 | 1.54 | 0.85 | 0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.74% | 15.72% | 17.20% | 17.95% |
| Free Cash Flow Growth | 32.51% | 144.98% | 335.02% | -113.42% |
| Safety | ||||
| Net Debt / EBITDA | 2.05 | 1.85 | 1.73 | 2.17 |
| Interest Coverage | 4.73 | 6.75 | 7.48 | -13.04 |
| Efficiency | ||||
| Inventory Turnover | 0.38 | 0.28 | 0.30 | 0.32 |
| Cash Conversion Cycle | 209.17 | 222.75 | 242.58 | 174.76 |